Viz.ai and UTMB Announce Collaboration to Accelerate Recruitment in the CHESS Study with Viz Subdural Solution
23 Mayo 2024 - 1:17PM
Business Wire
AI-powered care coordination to help increase
enrollment rates and reduce time to randomization in chronic
subdural hematoma
Viz.ai, the leader in AI-powered disease detection and
intelligent care coordination, and the University of Texas Medical
Branch at Galveston (UTMB), an academic health institution of The
University of Texas System, have announced a collaboration to
incorporate Viz Subdural software into the Chronic Subdural
Hematoma Treatment with Embolization Versus
Surgery Study (CHESS).1
A chronic subdural hematoma (cSDH) is an old clot of blood on
the surface of the brain beneath its outer covering. These
liquefied clots most often occur in patients aged 60 and older who
have brain atrophy, a shrinking or wasting away of brain tissue due
to age or disease.2 As the population ages, cSDH is predicted to be
the most common cranial neurosurgical condition by 2030.3 CHESS
will collect safety and efficacy data in patients with a moderately
symptomatic convexity cSDH.
“CHESS is designed to be the first US randomized controlled
trial to provide evidence on the safety and efficacy of standalone
middle meningeal artery embolization (MMAE) vs surgical drainage
using particle embolization,” said Peter Kan, MD, MPH, FRCSC,
FAANS, Professor and Chair, Department of Neurosurgery, University
of Texas Medical Branch. “Viz.ai’s Subdural tool holds the promise
of efficiently identifying prospective participants, thereby aiding
in the timely completion of this important trial.”
The Viz Subdural algorithm was approved in 2022 as the first
SDH-specific AI-powered detection and care coordination platform
with the ability to identify suspected cases of acute and chronic
subdural bleeds, and then quickly notify the care team to review
the patient case and make a treatment decision if necessary. In the
CHESS trial, Viz.ai will notify investigators immediately when it
detects a patient who has suspected SDH and meets the eligibility
criteria for enrollment. Study investigators can measure chronic
bleeds4 and coordinate subject enrollment easily and securely
through Viz.ai’s dynamic, mobile, HIPAA-compliant platform.
“Patient enrollment is the most time-consuming and costly aspect
of the clinical trial process,” said Prem Batchu-Green, Vice
President of Clinical at Viz.ai. “By deploying Viz.ai for the CHESS
study, we are not only reducing the manual burden of patient
identification on research staff but also improving SDH detection
and workflow as well as increasing SDH awareness, physician
engagement, clinical specialist attendance, and case
collaboration.”
1 The study was funded by the National
Institute of Neurological Disorders and Stroke, of the National
Institutes of Health, under grant award number 1UG3NS128397-01A1.
The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National
Institutes of Health.
2 Chronic subdural hematomas. UCLA Health.
(n.d.).
https://www.uclahealth.org/medical-services/neurosurgery/conditions-treated/chronic-subdural-hematomas
3 Hoffman et al. (n.d.). Management of
chronic subdural hematoma with the subdural evacuating port system:
Systematic review and meta-analysis.
https://pubmed.ncbi.nlm.nih.gov/33775320/
4 Viz Subdural is currently available
commercially for triage and notification. Measuring SDH is not
available for commercial use.
About Viz.ai
Viz.ai is the pioneer in the use of AI algorithms and machine
learning to increase the speed of diagnosis and care across 1,600+
hospitals and health systems in the U.S. and Europe. The AI-powered
Viz.ai One™ is an intelligent care coordination solution that
identifies more patients with a suspected disease, informs critical
decisions at the point of care, and optimizes care pathways and
helps improve outcomes. Backed by real-world clinical evidence,
Viz.ai One delivers significant value to patients, providers, and
pharmaceutical and medical device companies. For more information
visit viz.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523924738/en/
Olivia Schlabach olivia.schlabach@finnpartners.com